Skip to main content
LLY
NYSE Life Sciences

研究性Retatrutide显示23.7%的体重减轻；礼来公司的第一季度收益报告即将发布

feedReported by Wiseek News
Sentiment info
Positive
Importance info
8
Price
$852.63
Mkt Cap
$804.239B
52W Low
$623.78
52W High
$1,133.95
Market data snapshot near publication time

summarizeSummary

礼来公司的研究性药物Retatrutide在临床试验中显示出非常有前途的疗效，平均体重减轻达23.7%，这是其强大的GLP-1管道的重大进展。这个积极的更新是在公司准备在今日市场开盘前发布2026年第一季度收益报告之际发布的，分析师预计将会有强劲的业绩，包括178.2亿美元的收入，这将受到其减重药持续需求的驱动。强劲的Retatrutide数据加强了礼来公司在利润丰厚的肥胖症市场中的领导地位，并降低了一个关键的未来增长驱动因素的风险。交易者将密切关注实际的第一季度结果，以寻找任何惊喜以及有关Retatrutide预计在年底前的七个第三阶段读数的进一步细节。

在该公告发布时，LLY的交易价格为$852.63，交易所为NYSE，所属行业为Life Sciences，市值约为$8042.4亿。 52周交易区间为$623.78至$1,133.95。 这则新闻被评估为积极市场情绪，重要性评分为8/10。 来源：Wiseek News。

show_chartPrice Chart

Share this article

Copied!

feed LLY - Latest Insights

LLY
May 01, 2026, 7:57 AM EDT
Source: Reuters
Importance Score:
8
Lilly's Foundayo Oral Obesity Drug Reaches Nearly 6,000 Prescriptions in Third Week Post-Launch
Sentiment: Neutral
View Wiseek Article
LLY
Apr 30, 2026, 11:25 AM EDT
Filing Type: 10-Q
Importance Score:
9
Eli Lilly Reports Exceptional Q1 Growth Driven by Mounjaro & Zepbound, Announces $1.1B Acquisition and $2.3B Share Repurchase
Sentiment: Positive
View Wiseek Article
LLY
Apr 30, 2026, 10:50 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Lilly USA President Foresees Strong GLP-1 Persistence in Medicare Population
Sentiment: Positive
View Wiseek Article
LLY
Apr 30, 2026, 10:17 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Medicaid Access Loss Dents Lilly's Q1 Prescription Growth by High Single Digits
Sentiment: Negative
View Wiseek Article
LLY
Apr 30, 2026, 10:02 AM EDT
Source: dpa-AFX
Importance Score:
8
Eli Lilly to Acquire Ajax Therapeutics for Up to $2.3 Billion, Boosting Blood Cancer Pipeline
Sentiment: Positive
View Wiseek Article
LLY
Apr 30, 2026, 7:03 AM EDT
Filing Type: 8-K
Importance Score:
9
Eli Lilly Reports Soaring Q1 Revenue & EPS, Raises Full-Year Guidance, and Secures Key FDA Approval
Sentiment: Positive
View Wiseek Article
LLY
Apr 30, 2026, 6:45 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Eli Lilly Projects $82B-$85B in Full-Year Revenue
Sentiment: Neutral
View Wiseek Article
LLY
Apr 29, 2026, 4:07 PM EDT
Source: Wiseek News
Importance Score:
8
Investigational Retatrutide Shows 23.7% Weight Loss; Eli Lilly's Q1 Earnings Report Imminent
Sentiment: Positive
View Wiseek Article
LLY
Apr 29, 2026, 1:44 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Weight-Loss Drug Demand Fuels Expected Triple-Digit Q1 Profit Growth for Eli Lilly
Sentiment: Positive
View Wiseek Article
LLY
Apr 29, 2026, 1:18 PM EDT
Filing Type: PX14A6G
Importance Score:
7
Shareholders Push for Independent Board Chair Citing New Antitrust Allegations and Legal Risks
Sentiment: Negative
View Wiseek Article